海外の治験の状況「前立腺癌」での検索結果
107件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States
- 2013-10-31
Not Recruiting
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL COMPARING ORTERONEL (TAK-700) PLUS PREDNISONE WITH PLACEBO PLUS PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- Australia, Belgium, Canada, Czech Republic, Estonia, Finland, France, Greece, Hungary, Italy, Netherlands, New Zealand, Poland, Singapore, Slovakia, Turkey, United States
- 2011-08-05
Not recruiting
- PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers
- Diagnostic Imaging
- Austria, United States
- 2011-01-31
Not recruiting
- Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
- Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer;Cancer;Cataract;Low Bone Mineral Density;Osteopenia;Osteoporosis;Prostate Cancer
- Australia, Bulgaria, Canada, Czech Republic, Czechia, France, Greece, Hungary, India, Latvia, Mexico, New Zealand, Poland, Russian Federation, Slovakia, Slovenia, South Africa, Ukraine, United States
- 2009-06-18
Not Recruiting
- A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic - D4320C00014
- hormone-resistant prostate cancer br>MedDRA version: 6.1 Level: LLT Classification code 10062904 Term:
- Austria, Belgium, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Portugal, Sweden, United Kingdom
- 2007-07-12
Not Recruiting
- A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
- Prostate Cancer at High Risk of Relapse After Radical Prostatectomy MedDRA version: 8 Level: PT Classification code 10060862
- Austria, Belgium, Germany, Hungary, Italy, United Kingdom
- 2005-11-04
Not Recruiting
- A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Belgium, Germany, India, Netherlands, Poland, Russian Federation, South Africa, United Kingdom, United States
- 2012-04-30
Not Recruiting
- An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Czech Republic, Germany, Lithuania, Poland, Slovakia, Taiwan, Province of China, United States
- 2015-10-29
Not Recruiting
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
- Metastatic Castration- Resistant Prostate Cancer (mCRPC);C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, Province of China, United Kingdom, United States
- 2014-10-01
Not Recruiting
- PET/CT (positron emission tomography/computed tomography) imaging using [68Ga]RM2 (radioactive PET tracer) for detection of tumors in patients with primary prostate cancer.
- Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01];Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01];Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Austria, Finland, United States
- 2015-02-18
